AVIR240517C7500
- 0.05
- 0.000.00%
Atea Pharmaceuticals Newsroom
GFS, PETS and CYTK Are Among After Hour Movers
Express News | Atea Pharmaceuticals Announced It Will Presents New Data Showcasing Potential Best-in-class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus At EASL Congress 2024
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q1 2024 Earnings Conference
The following is a summary of the Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript:Financial Performance:Atea Pharmaceuticals Inc. ended Q1 2024 with a cash equivalent and marketable
Express News | Atea Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $4 From $5
Atea Pharmaceuticals | 10-Q: Quarterly report
Express News | Atea Pharmaceuticals Inc: Qtrly Shr Loss $0.75
Express News | Atea Pharmaceuticals Q1 2024 GAAP EPS $(0.75) Misses $(0.61) Estimate
Atea Pharmaceuticals 1Q Loss/Shr 75c >AVIR
Atea Pharmaceuticals 1Q Loss/Shr 75c >AVIR
Press Release: Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expect
Notable Earnings After Tuesday's Close
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antivi
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious
Express News | Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir For COVID-19 In High-Risk Patients
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Atea Pharmaceuticals: Balancing Promising Prospects With Clinical and Regulatory Risks
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q4 2023 Earnings Conference
The following is a summary of the Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript:Financial Performance:Atea Pharmaceuticals reported an increase in R&D expenses for Q4 and full yea
Q4 2023 Atea Pharmaceuticals Inc Earnings Call
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAtea Pharmaceuticals b
Atea Pharmaceuticals GAAP EPS of -$0.47 Beats by $0.03